We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Lantheus (LNTH) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Lantheus Holdings (LNTH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Lantheus Holdings is a member of our Medical group, which includes 1154 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Lantheus Holdings is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for LNTH's full-year earnings has moved 15.1% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that LNTH has returned about 62% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -2.1% on a year-to-date basis. This shows that Lantheus Holdings is outperforming its peers so far this year.
Another stock in the Medical sector, Novo Nordisk (NVO - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 17.6%.
In Novo Nordisk's case, the consensus EPS estimate for the current year increased 9.6% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Lantheus Holdings belongs to the Medical - Products industry, a group that includes 101 individual companies and currently sits at #164 in the Zacks Industry Rank. On average, this group has gained an average of 2.1% so far this year, meaning that LNTH is performing better in terms of year-to-date returns.
On the other hand, Novo Nordisk belongs to the Large Cap Pharmaceuticals industry. This 12-stock industry is currently ranked #102. The industry has moved -2.2% year to date.
Investors with an interest in Medical stocks should continue to track Lantheus Holdings and Novo Nordisk. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Lantheus (LNTH) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Lantheus Holdings (LNTH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Lantheus Holdings is a member of our Medical group, which includes 1154 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Lantheus Holdings is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for LNTH's full-year earnings has moved 15.1% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that LNTH has returned about 62% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -2.1% on a year-to-date basis. This shows that Lantheus Holdings is outperforming its peers so far this year.
Another stock in the Medical sector, Novo Nordisk (NVO - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 17.6%.
In Novo Nordisk's case, the consensus EPS estimate for the current year increased 9.6% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Lantheus Holdings belongs to the Medical - Products industry, a group that includes 101 individual companies and currently sits at #164 in the Zacks Industry Rank. On average, this group has gained an average of 2.1% so far this year, meaning that LNTH is performing better in terms of year-to-date returns.
On the other hand, Novo Nordisk belongs to the Large Cap Pharmaceuticals industry. This 12-stock industry is currently ranked #102. The industry has moved -2.2% year to date.
Investors with an interest in Medical stocks should continue to track Lantheus Holdings and Novo Nordisk. These stocks will be looking to continue their solid performance.